The U.S. Food and Drug Administration (FDA) issued its third draft guidance under the Real-World Evidence (RWE) Program on November 29, 2021. In Real-World Data: Assessing Registries to.
Toronto, ON (PRWEB) December 01, 2021 Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical